1083326-19-5

Basic information

• Product Name: N-(5-bromopyridin-3-yl)cyclopropanesulfonamide
• Synonyms: N-(5-bromopyridin-3-yl)cyclopropanesulfonamide
• CAS NO: 1083326-19-5
• Molecular Formula: C₈H₉BrN₂O₂S
• Molecular Weight: 277.13826
• Mol File: 1083326-19-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(5-bromopyridin-3-yl)cyclopropanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-bromopyridin-3-yl)cyclopropanesulfonamide(1083326-19-5)
• EPA Substance Registry System: N-(5-bromopyridin-3-yl)cyclopropanesulfonamide(1083326-19-5)

Safety Data

• Hazardous Substances Data: 1083326-19-5(Hazardous Substances Data)

Usage

General Description

N-(5-bromopyridin-3-yl)cyclopropanesulfonamide is a chemical compound with a cyclopropane ring and a sulfonamide group attached to a pyridine ring. It is a heterocyclic compound with potential applications in medicinal chemistry as a building block for developing pharmaceutical drugs. The presence of the bromine atom makes it useful for chemical reactions such as substitution and coupling reactions. The cyclopropane ring adds rigidity to the molecule and can influence the pharmacological properties of any drug molecules derived from it. Overall, this compound has potential as a versatile intermediate in the synthesis of pharmaceutical compounds.

Upstream product

• 13535-01-8 3-amino-5-bromopyridine 
• 139631-62-2 cyclopropanesulfonyl chloride 

Downstream Products

• 1083325-76-1 N-{5-[3-(4-{[2-(methyloxy)phenyl]sulfonyl}-1-piperazinyl)-6-quinoxalinyl]-3-pyridinyl}cyclopropanesulfonamide 

Relevant articles and documents

NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN

The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of P13 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.